{"name":"Nippon Shinyaku Co., Ltd.","slug":"nippon-shinyaku-co-ltd","ticker":"","exchange":"","domain":"nipponshinyaku.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1969-01-01","label":"Cytarabine first approved","drug":"Cytarabine","drugSlug":"cytarabine","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Cytarabine","genericName":"Cytarabine","slug":"cytarabine","indication":"Acute lymphoid leukemia","status":"marketed"}]}],"pipeline":[{"name":"Cytarabine","genericName":"Cytarabine","slug":"cytarabine","phase":"marketed","mechanism":"Cytarabine inhibits DNA polymerase and incorporates into DNA/RNA, killing cells in S-phase.","indications":["Acute lymphoid leukemia","Acute myeloid leukemia, disease","Acute promyelocytic leukemia, FAB M3","Lymphomatous meningitis","Meningeal Leukemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxPWVVibmYxNmNxZmptLUl6OXBTRXluMUpEWkY2SXJtbmd0bmRadVRRMTdIZ0VDVTdSSHpxdWpGdlVyLTBubThMbHU2WjB4OVVjTGVreEJkd2Fjei03YXhiM3pJZC1DQ0xqa1UtbXVPQl9kMks4WG9BaWNyekh0QkFCbFdvVWlMYXplMi05SFdwWDI2djNJNWs0UklwNHJidDZNVGg2UDlkSUJCNVdyX1VkYS01TW5wQ2p4cTE4V3VzTUZWQ1RjaWZNVTI1c3M2c3NQYzlNbmNTYnQ3UjZwMnU1c0hUNVZIUGhBTVhzRmZwcjVRV293cGNRVGVzSmQwUEhmYUtDUEp5RlRkcDdWWnB4cl8wbjdSYkdNb3hRRXV2SUxFS2laLUpEWGo3VDhuMUdvenB5MURCcTQ?oc=5","date":"2026-03-09","type":"trial","source":"prnewswire.com","summary":"Brogidirsen (NS-089/NCNP-02) 4.5-Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2026 MDA Clinical & Scientific Conference - prnewswire.com","headline":"Brogidirsen (NS-089/NCNP-02) 4.5-Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at ","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-04","type":"pipeline","source":"simplywall.st","summary":"Nippon Shinyaku Co., Ltd. (TSE:4516) Stock Catapults 32% Though Its Price And Business Still Lag The Market - simplywall.st","headline":"Nippon Shinyaku Co., Ltd. (TSE:4516) Stock Catapults 32% Though Its Price And Business Still Lag The Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxNXzdyN2NTaXZmaXNLb1FhQ0VId25UWGM0WGpyUHUxc2JCaUVlejQ3b242Q2NyWDF4cFphYU10SlhtWDdRZEpFUW9RcWdtSW9oZGZDaVU4ZnFqTEtwemVqRmRwcHptR2V4UklYZS14Y3F1YWZObUFfV3FFb1U2QXRSeXdua0RqS2JwQ3JGcjQtb0pjXzFHTHlSYVY1WmN4VGJiMWd2QVQ4dHlZZ3lVRTRuSEt2WTFOSmhXYTFSRkZFNGVmNS1CSm5WNUt2MUkxNkRCWEI4ejhHZ0YwUEIyNmRNLXQ4WWZ4WDJsU1NLUUw3NElHQWhHNEpNZmUtck0yQWhRbkJKR0swMFhmWnRna2xEeFhvN05ZeFBZeW00T3hpb1ZIeUVaaE5NX0Vjb2VDMlJY?oc=5","date":"2025-10-14","type":"trial","source":"prnewswire.com","summary":"Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2025 World Muscle Society Congress - prnewswire.com","headline":"Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOSXc0dnAyTUFBWF9vNnZ6S0FRQS1QM05EcXBlYW1NVnMzSGNWM05TQWJ5aWZ3dllZMTd1T2NJc0xfUmtYMDVIcHNoQVhSUkpXdXNDX0p6ejZCUUVSaEpmenk4WWd1bmx3SW4teElKV1lvQVNGdzFFLWMyN1owRGhlS2U0bHZtRUQtTFZqN19OT1dQZjQ?oc=5","date":"2025-09-22","type":"pipeline","source":"BioWorld News","summary":"NS Pharma’s NS-051 designated orphan drug for DMD - BioWorld News","headline":"NS Pharma’s NS-051 designated orphan drug for DMD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxNeHhTa0tkeUxGWm9FVkxxaUN1V2FiQ0xfX29FQndTN1dhM0NZVDJRQk1pZXkzZk41b0xMekJtNnZYQnh6OHUtczVEX2R3N2JlakRRWGItUWhOTVFHN0xjU243T2UzQVFUTEtmY1hYT1JkZVhTR3hNTTg0MEs3N05MY194Uzdid0RWbUVrTWh6Qi1OOFY1TGhGd09nd3oxZTR6cmw2eWFTSlJjMm1iTi1MZzVZMVpZTS1pZUNyTDM4Tm94TjE5R21rSFl2dUsxNVo0OGlZWWZoajBZOHY0NVRUVkQ1T3c5emkwS2VobTF3?oc=5","date":"2025-09-19","type":"regulatory","source":"prnewswire.com","summary":"FDA Grants Orphan Drug Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy - prnewswire.com","headline":"FDA Grants Orphan Drug Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE43YWZmalNrYmNvemxkU2tUWnVfLUpLdDZ4dG1MMTB3djVVSERoWTJiR3FiYzVDZ0gzdVdTVW9aS0w1eERyWGc5YUZVSm5EdEhMTEN1T0plYVpBc3JlVzVqeWZWa0VHLWMw?oc=5","date":"2025-09-09","type":"trial","source":"Wiley Online Library","summary":"Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study - Wiley Online Library","headline":"Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxOZjlGcFF1NGZRNjNHNnc0RkxMa2ROckhqOXhlSVU4WGktYklnOHN1NmYyNVBxNmhtMFAtcXRLckFQQjhpd05ZbTlpREFWU3hjeXFoZHdscHJBdTg2c2JweTNxVk5sWmt3MjBYdmxZcnZqakh0UzhXV1dkYlhwS01TejRLbnoyaUQtQ2M2elhyNlpOQWpRdGpza0lhUGl5NUNxYWktYmJvdGd0cllfeHV2clplU2pKZ1VnZThwb0VYMlRxdVFvVXJ6anY2eWhxY2h1am5uNEFrZVRya291T2pRVlRMVEV6Y0VUWkFyZnRMNkFGRWdxTVV2VEtn?oc=5","date":"2025-09-09","type":"regulatory","source":"prnewswire.com","summary":"FDA Grants Fast Track Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis - prnewswire.com","headline":"FDA Grants Fast Track Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNZGRTaUtseVVrRElVdG1WSTRUWUMyMXd3OUVjTzJWREo5LVZZLXQ3UjdyTHNrTVJrems4dEtwNXB1OEM2cFJua0Q0TWE0R1hfWlNFdjNuREltb1pqODJadkloTDdhNFdDY3hVYlJ5aGVzeG1tNVFrNkl6TWpIZVNZNjdzNzR6Tm53WldYekF4QjNKTHJHbTRGZGpiank2NWNCbU1HOExDZ1MtTzBibHl0SUJhanZFQ2RVZUxnWVVEUFN5MUhsU19SSTdvOWZrb1RheGJxLXJVUWxLMXdDZm16V2E1VDZ0ZGtwZ0RJUllHelFiR19YWG5aanhDakw?oc=5","date":"2025-07-01","type":"pipeline","source":"prnewswire.com","summary":"NS Pharma Announces Strategic Alliance with Boston Children's Hospital to Develop New Therapies for Rare Diseases - prnewswire.com","headline":"NS Pharma Announces Strategic Alliance with Boston Children's Hospital to Develop New Therapies for Rare Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQSnBsaV9JajlCWk1IWGxnUVlsMEx5N3JzMUZwMVNSZm4wN051bFB6c0NURXV1UFIwRVJ5Yzg5bjdpTWRNYVlWcTBRZEVQM3cyZ1pELTM1V0laTTlMSC1sV2VyWmpVa05WNF83V0ZUUDFDZi12SXNudEpRV0NiVmhjOXgxYV9rMVBTU0U3TVQ5X25xUTVzdzBpUU5vV2gyekZCNUtIbXFNUGwyZ3VRX3ZhRQ?oc=5","date":"2025-01-15","type":"deal","source":"Contract Pharma","summary":"Regenxbio, Nippon Shinyaku Partner for MPS II, MPS I Gene Therapies - Contract Pharma","headline":"Regenxbio, Nippon Shinyaku Partner for MPS II, MPS I Gene Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPUlktZjlObTNHRXR3MDdIdnhfQ3c3MUM1MF9jZERtRmxrbEg1UXMtUnBzMFVMbDk0YXg0WGYySGNiRlBHQ2dEemFxYk51UjRYeXAyYUJqRG05cEFJN1VBaTk2M2FzY2VlZ2VIQUtSeW8tNGVMZ2tqRXdYaEdIMkt4ZzNGVUQ5TDA?oc=5","date":"2024-05-28","type":"trial","source":"pharmaphorum","summary":"Nippon Shinyaku’s DMD drug fails confirmatory trial - pharmaphorum","headline":"Nippon Shinyaku’s DMD drug fails confirmatory trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQbGtzWEh1el9VOWxsXzg0d1RQcEFRQkgxcUxPc2dDNHdDZ1RrT1FWYjI0enJDQ1NtZW80MXZwdmdaZHdmZDVwZ3dxYW9STWlBeGJBRXE2X3pBUHlfQkk3NFZhQkxPRUtkcmxlY1dDcC1lNmc4Qjdob0xyYzExeDE3MkJGZTlGdXFIa01lUGxkWWJfQ245eFhVZ2k1cWRvazl3aDVUcFVzRQ?oc=5","date":"2023-08-04","type":"regulatory","source":"NeurologyLive","summary":"FDA Clears NS-050/NCNP-03 for Phase 1/2 Trial of Duchenne Muscular Dystrophy - NeurologyLive","headline":"FDA Clears NS-050/NCNP-03 for Phase 1/2 Trial of Duchenne Muscular Dystrophy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPazRzUG9scWRYVWVyTkJUTnhsT2diYk1GN3ktQ19MajR1MnEzd0dtcVJLSWxRUDBtWkxsTzVQbzEyUWh6Tm1DUFBRR2gyTlRHa3JHYlNOVW9WejlsLXNHZUJRNVhGRlI2Z1F0Wkswd0haaHduNW9kV3NEejg4cHpmbHA0Mzh3UlVzZG5aVWlNX1ktOWo5VVpKdHl4d3BtNXF5?oc=5","date":"2022-02-04","type":"trial","source":"NeurologyLive","summary":"Capricor Announces Partnership for DMD Therapy CAP-1002 Ahead of Phase 3 Study - NeurologyLive","headline":"Capricor Announces Partnership for DMD Therapy CAP-1002 Ahead of Phase 3 Study","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}